 Bicycle Therapeutics plc NASDAQ: BCYC is down 30 after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase results from the Phase 12 study of BT8009. BT8009 is a second-generation BTC targeting Nectin-4 that the company is developing. 